This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: April 15, 2010
Last updated: September 20, 2011
Last verified: September 2011
The primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of CLDE during a 29-day treatment period of azithromycin ophthalmic solution, 1%, compared to rewetting drops

Condition Intervention Phase
Contact Lens Dry Eye Drug: azithromycin ophthalmic solution, 1% Drug: Visine® for Contacts® Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Subject-reported comfortable contact lens daily wear time (hours/day) at Week 4 Endpoint [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Subject-reported comfortable contact lens daily wear time, excluding Week 4 Endpoint [ Time Frame: 2 weeks ]
  • Subject-reported duration of total contact lens daily wear [ Time Frame: 4 weeks ]
  • Subject-reported rating of overall eye dryness [ Time Frame: 4 weeks ]
  • Contact Lens-Related Dry Eye Questionnaire [ Time Frame: 4 weeks ]
  • Tear hyperosmolarity (mOsm) [ Time Frame: 4 weeks ]
  • Habitual low-contrast visual acuity (LCVA) [ Time Frame: 4 weeks ]

Enrollment: 50
Study Start Date: March 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: azithromycin ophthalmic solution, 1% Drug: azithromycin ophthalmic solution, 1%
1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
Experimental: rewetting drops Drug: Visine® for Contacts®
1-2 drops QID for the treatment period (29 ± 1 day)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a history of and current complaint of CLDE.
  • Use properly fitted daily-wear soft contact lenses.
  • Able to wear contact lenses for at least 8 hours a day.
  • If female, are non-pregnant or non-lactating.

Exclusion Criteria:

  • Have changed brand of contact lens or care solutions within one month prior to Visit 1.
  • Use extended (overnight) wear contact lenses.
  • Have a clinically significant ophthalmic abnormality.
  • Have had cauterization of the punctum or have had punctal plugs (silicone or collagen) inserted or removed within the 90 days prior to the screening.
  • Have any active ongoing ocular infection or ocular disease.
  • Have a serious medical condition which could confound study assessments.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01105624

United States, Ohio
The Ohio State University, College of Optometry
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Chair: Reza Haque, MD, PhD Medical Monitor
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mike Schiewe, Associate Director, Inspire Identifier: NCT01105624     History of Changes
Other Study ID Numbers: 041-117
Study First Received: April 15, 2010
Last Updated: September 20, 2011

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions
Ophthalmic Solutions
Anti-Bacterial Agents
Anti-Infective Agents processed this record on August 21, 2017